Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr. Martens Plc ( (GB:DOCS) ) has shared an announcement.
Dr. Martens reported a return to profit growth in the 52 weeks to 29 March 2026, with adjusted profit before tax rising 61% to £55m despite a 2.9% decline in revenue to £764.9m as the company deliberately reduced clearance and off-price activity. Shoes were a standout category with 19% revenue growth, gross margin improved by 120 basis points to 66.2%, net debt fell, and the dividend was maintained at 2.55p per share, signalling confidence in cash generation and balance sheet strength.
The company said it has completed the “pivot” phase of its three-stage strategy, shifting from a channel-led to a consumer-first model by cutting discounted pairs in US wholesale, boosting new product families and reorganising into a market-led structure. Dr. Martens plans to enter a scale phase in FY27 by investing more in brand building, upgrading high-potential stores and deepening wholesale partnerships, expecting further PBT growth through operational leverage even as retail strategy changes create a short-term revenue headwind in a volatile macro environment.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Spark’s Take on DOCS Stock
According to Spark, TipRanks’ AI Analyst, DOCS is a Neutral.
Dr. Martens Plc’s overall stock score reflects a mix of financial challenges and strategic progress. The most significant factor is the company’s financial performance, which is hindered by declining revenue and profitability. Technical analysis indicates bearish momentum, while valuation suggests the stock is overvalued. Positive corporate events and earnings call insights provide some optimism, but challenges remain.
To see Spark’s full report on DOCS stock, click here.
More about Dr. Martens Plc
Dr. Martens plc is a British footwear company best known for its iconic boots and shoes, including the 1460 boot and 1461 shoe, as well as loafers and Mary Janes. The brand operates through direct-to-consumer and wholesale channels across the Americas, EMEA and APAC, and is increasingly focusing on higher-margin, full-price sales and a consumer-first retail model.
Average Trading Volume: 1,186,012
Technical Sentiment Signal: Sell
Current Market Cap: £602.6M
For an in-depth examination of DOCS stock, go to TipRanks’ Overview page.